Related Experiment Video
Updated: Feb 19, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Percutaneous Left Atrial Appendage Closure With the LAmbre Device for Stroke Prevention in Atrial Fibrillation: A
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China; Cardiovascular Research Institute of Wuhan University, Wuhan, People's Republic of China; Hubei Key Laboratory of Cardiology, Wuhan, People's Republic of China.
Insights
Left atrial appendage (LAA) closure using the LAmbre device effectively prevents stroke in patients with nonvalvular atrial fibrillation (NVAF). This minimally invasive procedure demonstrated a high success rate and favorable safety profile over 12 months.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- The left atrial appendage (LAA) is a primary source of thrombi in nonvalvular atrial fibrillation (NVAF) patients.
- Over 90% of blood clots in NVAF originate from the LAA.
Purpose of the Study:
- To evaluate the clinical outcomes of LAA closure using the LAmbre device.
- To assess the efficacy and safety of LAmbre device for stroke prevention in NVAF patients.
Main Methods:
- A prospective, multicenter study.
- Involved 153 NVAF patients with a CHADS2 score ≥1.
- Utilized the LAmbre closure system for LAA occlusion.
Main Results:
- Successful LAA occlusion achieved in 152 out of 153 patients.
- Serious complications reported in 5 patients.
- During 12-month follow-up: 2 ischemic strokes, 1 incomplete sealing, 0 device embolizations.
Conclusions:
- LAA closure with the LAmbre device shows promising results for stroke prevention in NVAF.
- The LAmbre system is a viable option for reducing stroke risk in this patient population.
Objectives:
The authors sought to assess the clinical outcomes of left atrial appendage (LAA) closure with the LAmbre closure system in patients with nonvalvular atrial fibrillation (NVAF).
Background:
Over 90% of thrombi are located in the LAA in NVAF patients.
Methods:
A prospective, multicenter study was conducted in 153 NVAF patients with CHADS2 score ≥1.
Results:
The LAA was successfully occluded in 152 patients. Serious complications occurred in 5 patients. During the 12-month follow-up, ischemic stroke occurred in 2 patients, 1 patient had incomplete LAA sealing, and there was no device embolization.
Conclusions:
LAA closure with the LAmbre device shows encouraging results for stroke prevention.
